Association of Urinary Cadmium with Mortality in Patients at a Coronary Care Unit

Ching-Wei Hsu1,2,3, Cheng-Hao Weng1,2,3, Dan-Tzu Lin-Tan1,2,3, Pao-Hsien Chu3,4, Tzung-Hai Yen1,2,3, Kuan-Hsing Chen1,2,3, Chung-Yin Lin1,2,3, Wen-Hung Huang1,2,3*

1 Department of Nephrology, Division of Clinical Toxicology, Chang Gung Memorial Hospital, Taipei, Taiwan, 2 Department of Nephrology, Division of Clinical Toxicology, Lin-Kou Medical Center, Taoyuan, Taiwan, 3 Chang Gung University and School of Medicine, Taoyuan, Taiwan, 4 Division of Cardiology, Chang Gung Memorial Hospital, Lin-Kou Medical Center, Taoyuan, Taiwan

* williammedia@yahoo.com.tw

Abstract

Background

Determine the effect of the day 1 urinary excretion of cadmium (D1-UE-Cd) on mortality of patients admitted to a coronary care unit (CCU).

Methods

A total of 323 patients were enrolled in this 6-month study. Urine and blood samples were taken within 24 h after CCU admission. Demographic data, clinical diagnoses, and hospital mortality were recorded. The scores of established systems for prediction of mortality in critically ill patients were calculated.

Results

Compared with survivors (n = 289), non-survivors (n = 34) had higher levels of D1-UE-Cd. Stepwise multiple linear regression analysis indicated that D1-UE-Cd was positively associated with pulse rate and level of aspartate aminotransferase, but negatively associated with serum albumin level. Multivariate Cox analysis, with adjustment for other significant variables and measurements from mortality scoring systems, indicated that respiratory rate and D1-UE-Cd were independent and significant predictors of mortality. For each 1 μg/day increase of D1-UE-Cd, the hazard ratio for CCU mortality was 3.160 (95% confidence interval: 1.944 – 5.136, p < 0.001). The chi-square value of Hosmer-Lemeshow goodness-of-fit test for D1-UE-Cd was 10.869 (p = 0.213). The area under the receiver operating characteristic curve for D1-UE-Cd was 0.87 (95% confidence interval: 0.81 – 0.93).

Conclusions

The D1-UE-Cd, an objective variable with no inter-observer variability, accurately predicted hospital mortality of CCU patients and outperformed other established scoring systems. Further studies are needed to determine the physiological mechanism of the effect of cadmium on mortality in CCU patients.
Introduction
Cadmium is a well-known toxic metal [1], and occupational or environmental exposure is implicated in several clinical conditions, such as renal dysfunction, bone disease, and some cancers [2]. Notably, renal tubular damage may develop following exposure to lower levels of cadmium than previously anticipated [3]. Cadmium has a long half-life in humans (10–30 years) [2] and is excreted mainly in urine, normally less than 2 μg/day in persons without occupational exposure [4]. There is a positive correlation between urinary cadmium excretion and cadmium body burden [5], so the total daily urinary excretion of cadmium is a better indicator of cadmium accumulation than blood cadmium in humans [5,6].

In clinical practice, several scoring models are used to evaluate illness severity and predict prognosis, such as Sequential Organ Failure Assessment (SOFA), Acute Physiology and Chronic Health Evaluation-II (APACHE II), RIFLE (Risk, Injury, Failure, Loss, End-stage kidney Disease) criteria, Simplified Acute Physiology Score (SAPS), and the Multiple Organ Dysfunction Score [7–11]. Additionally, Lakkireddy et al. [12] developed a scoring model to quantify the outcomes of critically ill cardiac patients, the Modified Mid America Heart Institute Coronary Care Unit (CCU) scoring system. In spite of the widespread use and acceptance of these scoring models, there can be significant inter-observer variability in assessing individual patients [10,13]. Moreover, implementation of these scoring systems can be difficult and time-consuming. Recently, our research team showed that urinary cadmium excretion on day 1 (D1-UE-Cd) of admission to an intensive care unit (ICU) can predict illness severity and mortality of critically ill patients [6]. However, the association between urinary cadmium excretion and illness severity and mortality remains uncertain for critically ill patients admitted to CCUs. Furthermore, there is no single and reliable variable that accurately predicts hospital mortality in this population.

In this study, we examined the correlation between urinary cadmium excretion and outcome of critically ill cardiac patients admitted to a CCU and compared the results to existed scoring systems for predicting outcome.

Methods
This clinical study was conducted in accordance with the Declaration of Helsinki and was approved by the Medical Ethics Committee of Chang Gung Memorial Hospital, a tertiary referral medical center in Taiwan. Written informed consent was obtained from every participant, and the study was approved by the Institutional Review Board of Chang Gung Memorial Hospital. All individual information was securely protected (by delinking identifying information from main data set) and available to investigators only. Furthermore, all the data were analyzed anonymously. This 6-month study examined the relationship between D1-UE-Cd with illness severity and mortality of critically ill patients admitted to a CCU.

Patients and data collection
All study participants were from the CCU of the Chang Gung Memorial Hospital from Jan 1, 2005 to June 30, 2005 and were at least 18 years-old. Patients with any of the following criteria were excluded: total urine less than 500 mL on day 1 of CCU admission; duration of CCU stay less than 1 day; duration of hospital stay more than 150 days; presence of end-stage renal disease and undergoing maintenance dialysis; readmission to the CCU; and history of occupational, residential, or other exposure to cadmium or history of intoxication from other heavy metals. We collected the following data for analysis: demographic data, laboratory data, duration of CCU and hospital stays, pre-existing chronic diseases, initial diagnosis and clinical conditions upon CCU admission, and data for scoring predictive indices and patient outcomes.
We recorded the total urine volume of patients during the first 24 h of CCU admission to calculate the amount of excretory cadmium in urine. All physicians who participated in this study were blinded to the results of D1-UE-Cd to reduce bias.

Clinical scoring systems

We used 3 scoring models to evaluate the severity of illness based on data collected on day 1 of CCU admission: APACHE II, SOFA, and RIFLE. The scores of the APACHE II [14,15] and SOFA [8] were calculated as previously described. The RIFLE criteria, which evaluates the stage of acute kidney injury (AKI) as defined by the Acute Dialysis Quality Initiative (ADQI) Group [16], was based on the increase of serum creatinine and/or the decrease of glomerular filtration rate and urine output.

Measurement of urinary cadmium

We collected urine samples in cadmium-free bottles and measured cadmium levels at 24 h after CCU admission. Urinary cadmium was measured as described by Jin et al. [17]. In particular, 500 μL of trace metal–grade distilled 0.8 M HNO₃ and 100 μL of urine were added to 1.5-mL Eppendorf tubes and then immediately agitated. After overnight refrigeration, the vessels were warmed to room temperature, whirl-mixed for 5–10 s, and then centrifuged for 5 min at 11,500 rpm. The supernatant was transferred to graphite furnace sampler cups. The cadmium levels of the acid-digested samples were measured by electrothermal atomic absorption spectrometry (SpectrAA-220 Zeeman; Varian, Palo Alto, CA, USA) with Zeeman’s background correction and an L’ovov platform. The detection limit for urinary cadmium concentration was 0.01 μg/L. Quality control was consistently confirmed by internal and external quality-control procedures. A certified commercially prepared product (Seronorm Trace Elements; Sero AS, Billingstads, Norway) was used to determine intra-batch accuracy and ensure inter-batch standardization. The coefficient of variation for the cadmium measurements was 5.0% or less. External quality control was maintained via participation in the National Quality Control Program conducted by the government of Taiwan.

Statistical analysis

The Kolmogorov-Smirnov test was applied for the distribution of the continuous variables. Unless otherwise stated, continuous variables were expressed as mean ± standard deviation or median with interquartile range (IQR), and categorical variables were expressed as number with percentage. We used the chi-square test or Fisher’s exact test to compare categorical data of survivors and non-survivors, and Student’s t-test or Mann-Whitney U test to identify the significance of differences between groups. To identify factors associated with D1-UE-Cd, we used a simple linear regression analysis for all variables. All potential variables (p < 0.05) from this simple linear regression were entered into multiple linear regression models with backward stepwise procedures. Data were expressed as standardized regression coefficients (β) and p values in the linear regression analysis.

We used the Cox proportional-hazard model to assess the effect of baseline variables on mortality, hazard ratios (HRs), and 95% confidence intervals (CIs) of mortality. A univariate Cox model was used to identify the association of all variables with mortality; variables with p-values less than 0.05 were entered into a multivariate Cox model with a forward stepwise procedure.

We used the Hosmer-Lemeshow (HL) test to assess goodness-of-fit in the models [18]. We applied receiver operating characteristic curve (ROC) to evaluate discrimination, the ability of the model to distinguish between death and survival, by assessing the area under ROC.
All statistical tests were two tailed, and a \( p \)-value less than 0.05 was considered statistically significant. Data were analyzed using StatView 2.0 for Windows (SAS Institute, Cary, NC) and SPSS version 18.0 for Windows XP (SPSS, Chicago, IL).

**Results**

**Patient characteristics**

A total of 323 critically ill cardiac patients (209 males and 114 females) in the CCU met our enrollment criteria and had complete medical records (Table 1). The mean patient age was 65.3 ± 15.0 years; mean body mass index (BMI) was 24.29 ± 4.57 kg/m². 151 patients (46.7%) were smokers. The median duration in the CCU was 4.0 days (IQR: 3.0–8.0), and the median duration of hospitalization was 11.0 days (IQR: 7.0–27.0). The median APACHE score was 10.0 (IQR: 5.75–17.0). The median SOFA score was 3.0 (IQR: 1.0–6.0), and the median D1-UE-Cd was 0.34 μg/day (IQR: 0.15–0.80). The 3 main causes of CCU admission were acute myocardial infarction (46.4%, \( n = 150 \)), class III/IV congestive heart failure (CHF) (24.8%, \( n = 80 \)), and arrhythmia (9.6%, \( n = 31 \)). The overall mortality rate was 10.5% (\( n = 34 \)).

Table 1 compares the baseline characteristics of survivors (\( n = 289 \)) and non-survivors (\( n = 34 \)). Non-survivors were more likely to have previously diagnosed chronic kidney disease, AKI, class III/IV CHF, circulatory shock, and acute respiratory failure. Survivors were more likely to be male, smokers, and have a higher BMI. Furthermore, non-survivors had longer CCU and hospital stays, higher APACHE II score, SOFA score, and RIFLE score, and higher levels of D1-UE-Cd.

Analysis of vital signs and biochemical data indicated that non-survivors had higher arterial pressure, pulse and respiratory rates, and levels of aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine. Survivors had higher scores on the Glasgow coma scale and higher levels of serum albumin (Table 2).

**Determinants of urinary cadmium excretion on day 1 of CCU admission**

Simple linear regression analysis (Table 3) indicated that D1-UE-Cd was positively associated with circulatory shock, pulse and respiratory rates, AST, white blood cell count, APACHE II and SOFA scores; however, D1-UE-Cd was negatively associated with sex, BMI, hyperlipidemia, hypertension, Glasgow coma scale score, mean arterial pressure, serum albumin, hemoglobin, and cardiac ejection fraction. After adjusting for potential confounding, multiple linear regression analysis with backward stepwise procedures indicated that pulse rate (\( \beta = 0.202, \ p = 0.002 \)) and AST level (\( \beta = 0.140, \ p = 0.027 \)) were positively associated with D1-UE-Cd, and that albumin level (\( \beta = -0.258, \ p < 0.001 \)) was negatively associated with D1-UE-Cd.

**Cox regression analysis for mortality of the CCU patients**

Univariate Cox regression analysis identified 20 potential predictors of mortality (Table 4), including sex, smoking, BMI, AKI, shock on admission, score of the Glasgow coma scale, mean arterial pressure, pulse and respiratory rates, serum albumin levels, AST, alanine aminotransferase, BUN, creatinine, hemoglobin, white blood cell count, APACHE II score, SOFA score, RIFLE score, and D1-UE-Cd.

We determined the independent effect of each predictor by entering these data into a multivariate Cox regression analysis with a forward stepwise method (Table 5). The results show that respiratory rate and D1-UE-Cd were independent predictors of mortality. The HR of CCU mortality for each increment of 1 breath/min was 1.139 (95% CI: 1.056–1.228, \( p = 0.001 \))
and the HR of CCU mortality for each increment of 1μg/day of urinary cadmium was 3.160
(95% CI: 1.944–5.136, p < 0.001).

Table 1. Baseline characteristics of study patients upon admission to the cardiac care unit (n = 323).

| Variable                              | Survivors (n = 289) | Non-survivors (n = 34) | P         |
|---------------------------------------|--------------------|------------------------|-----------|
| **Demographic data**                  |                    |                        |           |
| Age (years)                           | 64.9 ± 14.6        | 68.9 ± 16.5            | 0.140     |
| Sex (male)                            | 195 (67.5)         | 14 (41.2)              | 0.004     |
| Body mass index (kg/m²)               | 24.48 ± 4.6        | 22.64 ± 3.95           | 0.027     |
| Smoking (Yes)                         | 143 (49.5)         | 8 (23.5)               | 0.006     |
| CCU stay (days)                       | 4.0 (3.0–7.0)      | 11.0 (6.3–28.5)        | <0.001    |
| Hospital stay (days)                  | 11.0 (7.0–24.0)    | 19.5 (10.8–32.0)       | 0.028     |
| **Co-morbidities**                    |                    |                        |           |
| Previously diagnosed cardiovascular disease | 128 (44.3)        | 21 (61.8)              | 0.068     |
| Previously diagnosed chronic kidney disease | 48 (16.6)        | 13 (38.2)              | 0.005     |
| Previously diagnosed chronic pulmonary disease | 31 (10.7)        | 5 (14.7)               | 0.561     |
| Hyperlipidemia                        | 126 (43.6)         | 11 (32.4)              | 0.271     |
| Diabetes mellitus                     | 99 (34.3)          | 14 (11.8)              | 0.450     |
| Hypertension                          | 166 (57.4)         | 16 (47.1)              | 0.276     |
| **Diagnosis and clinical condition on admission** | | | |
| Acute myocardial infarction           | 138 (47.8)         | 12 (35.3)              | 0.152     |
| CHF class III and IV                  | 67 (23.2)          | 13 (38.2)              | 0.037     |
| Arrhythmia                            | 28 (9.7)           | 3 (8.8)                | 1.000     |
| Unstable angina                       | 25 (8.7)           | 0 (0.0)                | 0.091     |
| Aortic dissection                     | 10 (3.5)           | 0 (0.0)                | 0.608     |
| Post-CPCR                             | 4 (1.4)            | 2 (5.9)                | 0.130     |
| Hypertension crisis                   | 3 (1.0)            | 1 (2.9)                | 0.369     |
| Infective endocarditis                | 3 (1.0)            | 1 (2.9)                | 0.369     |
| Other                                 | 11 (3.8)           | 2 (5.9)                | 0.640     |
| Circulatory shock                     | 20 (6.9)           | 15 (44.1)              | 0.001     |
| Acute respiratory failure             | 72 (24.9)          | 15 (44.1)              | 0.024     |
| AKI                                   | 30 (10.4)          | 16 (47.1)              | <0.001    |
| **Predictive indices on admission**   |                    |                        |           |
| APACHE II score                       | 9.0 (5.0–16.0)     | 20.5 (15.3–25.0)       | <0.001    |
| SOFA score                            | 2.0 (1.0–5.3)      | 7.0 (4.3–9.8)          | <0.001    |
| RIFLE criteria (class F)              | 9 (3.1)            | 4 (11.8)               | <0.001    |
| D1-UE-Cd (μg/day)                     | 0.30 (0.14–0.63)   | 1.53 (0.80–3.07)       | <0.001    |

Data presented as mean ± standard deviation, number (percentage), and median (interquartile range). Cardiovascular diseases included stroke, ischemic heart disease, valve diseases and peripheral vascular diseases. Chronic kidney disease defined as persistent abnormal renal function (serum creatinine > 1.4 mg/dL) for 6 months at least. Chronic pulmonary diseases included asthma, chronic bronchitis, chronic obstructive pulmonary disease and lung fibrosis. Hyperlipidemia defined as diagnosed by a physician and required regular treatments with antilipidemic agents. Diabetes mellitus was diagnosed by a physician and required regular treatments with antihyperglycemic drugs. Hypertension defined as blood pressure > 140/90 mm Hg at least twice measurements and required regular treatments with antihypertensive drugs. Shock defined as mean arterial pressure < 60 mm Hg. Acute respiratory failure defined as acute onset of respiratory failure required ventilator support. Acute kidney injury defined as serum creatinine >2.0 mg/dL and/or daily urine amount <500 mL.

**Abbreviations here and below:** AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; CCU, coronary care unit; CHF, congestive heart failure; CPCR, cardiopulmonary cerebral resuscitation; D1-UE-Cd, day 1 urinary excretion of cadmium; RIFLE, Risk, Injury, Failure, Loss, End-stage kidney Disease; SOFA, Sequential Organ Failure Assessment.

doi:10.1371/journal.pone.0146173.t001
### Table 2. Baseline vital signs and biochemical data of study patients upon admission to the cardiac care unit (n = 323).

| Variable                 | Survivors (n = 289) | Non-survivors (n = 34) | P       |
|--------------------------|---------------------|------------------------|---------|
| **Vital signs**          |                     |                        |         |
| Glasgow Coma scale       | 13.6 ± 3.3          | 11.6 ± 4.2             | 0.011   |
| Mean arterial pressure (mm Hg) | 76.8 ± 15.9   | 86.7 ± 18.0            | 0.003   |
| Body temperature (°C)    | 36.9 ± 0.8          | 37.1 ± 1.2             | 0.186   |
| Pulse rate (beats/min)   | 83.8 ± 22.1         | 100.2 ± 25.2           | <0.001  |
| Respiratory rate (breaths/min) | 19.8 ± 5.0      | 22.7 ± 6.4             | 0.002   |
| **Biochemical data**     |                     |                        |         |
| PaO2/FiO2 (mm Hg)        | 274.1 ± 146.1       | 271.9 ± 175.4          | 0.938   |
| Albumin (g/dL)           | 3.43 ± 0.53         | 3.01 ± 0.55            | <0.001  |
| AST (IU/L)               | 38.0 (25.0–82.0)    | 51.0 (30.0–427.0)      | 0.017   |
| ALT (IU/L)               | 31.0 (19.0–58.3)    | 42.0 (14.0–239.0)      | 0.276   |
| Total bilirubin (mg/dL)  | 1.12 ± 1.60         | 1.00 ± 0.86            | 0.416   |
| BUN (mg/dL)              | 31.0 ± 24.8         | 45.1 ± 28.9            | 0.010   |
| Creatinine (mg/dL)       | 1.55 ± 1.23         | 2.12 ± 1.36            | 0.015   |
| Sodium (mmol/L)          | 138.6 ± 7.0         | 139.0 ± 6.4            | 0.722   |
| Potassium (mmol/L)       | 3.96 ± 0.63         | 3.97 ± 0.89            | 0.964   |
| Hemoglobin (g/dL)        | 13.3 ± 6.5          | 11.1 ± 3.2             | 0.055   |
| White blood cells (10³/µL) | 10.8 ± 4.2      | 12.8 ± 5.8             | 0.054   |
| Platelets (10³/µL)       | 209.3 ± 84.2        | 204.3 ± 81.3           | 0.740   |
| Cardiac ejection fraction (%) | 52.9 ± 18.3    | 46.8 ± 17.8            | 0.064   |

Data presented as mean ± standard deviation and median (interquartile range).

**Abbreviations here and below:** AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen.

### Table 3. Determinants of urinary cadmium excretion on day 1 of CCU admission in all study patients

| Variable                           | Simple Linear Regression β | P       | Backward Stepwise Multiple Linear Regression β | P       |
|------------------------------------|----------------------------|---------|-----------------------------------------------|---------|
| Sex                                | -0.124                     | 0.044   |                                               |         |
| Body mass index (kg/m²)            | -0.175                     | 0.004   |                                               |         |
| Hyperlipidemia                     | -0.171                     | 0.005   |                                               |         |
| Hypertension                       | -0.146                     | 0.017   |                                               |         |
| Shock                              | 0.233                      | <0.001  |                                               |         |
| Glasgow Coma scale                 | -0.228                     | <0.001  |                                               |         |
| Mean arterial pressure             | -0.174                     | 0.004   |                                               |         |
| Pulse rate (beats/min)             | 0.256                      | <0.001  | 0.202                                         | 0.002   |
| Respiratory rate (breaths/min)     | 0.143                      | 0.019   |                                               |         |
| Albumin (g/dL)                     | -0.308                     | <0.001  | -0.258                                        | <0.001  |
| AST (IU/L)                         | 0.171                      | 0.012   | 0.140                                         | 0.027   |
| Hemoglobin (g/dL)                  | -0.172                     | 0.005   |                                               |         |
| White blood cells (10³/µL)         | 0.236                      | <0.001  |                                               |         |
| Cardiac ejection fraction (%)      | -0.122                     | <0.001  |                                               |         |
| APACHE II score                    | 0.354                      | <0.001  |                                               |         |
| SOFA score                         | 0.291                      | <0.001  |                                               |         |

Data were expressed as standardized regression coefficients (β) and p values.
Analysis of goodness-of-fit and ROC curves for scoring systems and urinary cadmium levels

We measured goodness-of-fit of these models by use of the HL chi-square test and obtained the following results: (1) APACHE II (HL chi-square = 6.584, 8 degrees of freedom [df], p = 0.582) (2) SOFA (HL chi-square = 5.561, 7 df, p = 0.592) (3) RIFLE (HL chi-square = 0.001, 1 df, p = 1.000) (4) D1-UE-Cd (HL chi-square = 10.869, 8 df, p = 0.213).

We also used these data for ROC analysis (Fig 1). Computation of the area under the ROC curves (AUROCs) indicated that D1-UE-Cd (AUROC = 0.87 ± 0.03, 95% CI: 0.81–0.93, p < 0.001) had better discriminatory power than the APACHE II score (AUROC = 0.82 ± 0.03, 95% CI: 0.75–0.88, p < 0.001), SOFA score (AUROC = 0.78 ± 0.04, 95% CI: 0.71–0.86, p < 0.001), or RIFLE criteria (AUROC = 0.62 ± 0.06, 95% CI: 0.50–0.73, p < 0.001).

Discussion

The results of this 6 month study of mortality in patients at a CCU in Taiwan demonstrated that non-survivors had longer CCU and hospital stays, higher APACHE II, SOFA, and RIFLE scores, and greater D1-UE-Cd. Moreover, more non-survivors had previously diagnosed

Table 4. Univariate Cox analysis of risk factors for hospital death in all study patients according to baseline variables at the first day in the cardiac care unit. (P > 0.05 to remove)

| Variable                                      | HR (95% CI)       | P      |
|------------------------------------------------|-------------------|--------|
| Sex (female vs. male)                         | 2.804 (1.385–5.679) | 0.004  |
| Smoking (Yes vs. no)                          | 3.299 (1.427–7.628) | 0.005  |
| Body mass index (Increase of 1 kg/m²)         | 0.883 (0.805–0.969) | 0.008  |
| AKI on admission (Yes vs. no)                 | 3.228 (1.173–8.885) | 0.023  |
| Previously diagnosed chronic kidney disease (Yes vs. no) | 2.847 (1.389–5.836) | 0.004  |
| CHF class III and IV (Yes vs. no)             | 3.307 (1.704–6.419) | <0.001 |
| Mean arterial pressure (Increase of 1 mm Hg)  | 0.972 (0.952–0.993) | 0.009  |
| Pulse rate (Increase of 1 beat/min)           | 1.026 (1.013–1.039) | <0.001 |
| Respiratory rate (Increase of 1 breath/min)   | 1.080 (1.029–1.134) | 0.002  |
| Albumin (Increase of 1 g/dL)                  | 0.237 (0.112–0.458) | <0.001 |
| AST (Increase of 1 U/L)                       | 1.001 (1.000–1.002) | 0.001  |
| ALT (Increase of 1 U/L)                       | 1.001 (1.000–1.002) | 0.035  |
| BUN (Increase of 1 mg/dl)                     | 1.014 (1.005–1.023) | 0.003  |
| Creatinine (Increase of 1 mg/dL)              | 1.289 (1.082–1.535) | 0.004  |
| Hemoglobin (Increase of 1 g/dL)               | 0.786 (0.698–0.886) | <0.001 |
| White blood cells (Increase of 10^9/μL)       | 1.068 (1.002–1.139) | 0.044  |
| APACHE II score (Increase of 1)               | 1.107 (1.070–1.146) | <0.001 |
| SOFA score (Increase of 1)                    | 1.247 (1.152–1.349) | <0.001 |
| RIFLE score (Increase of 1)                   | 1.609 (1.222–2.119) | 0.001  |
| D1-UE-Cd (Increase of 1 μg/day)               | 1.751 (1.514–2.025) | <0.001 |

Abbreviations here and below: HR: Hazard Ratio; CI: confidence interval.

doi:10.1371/journal.pone.0146173.t004

Analysis of goodness-of-fit and ROC curves for scoring systems and urinary cadmium levels

We measured goodness-of-fit of these models by use of the HL chi-square test and obtained the following results: (1) APACHE II (HL chi-square = 6.584, 8 degrees of freedom [df], p = 0.582) (2) SOFA (HL chi-square = 5.561, 7 df, p = 0.592) (3) RIFLE (HL chi-square = 0.001, 1 df, p = 1.000) (4) D1-UE-Cd (HL chi-square = 10.869, 8 df, p = 0.213).

We also used these data for ROC analysis (Fig 1). Computation of the area under the ROC curves (AUROCs) indicated that D1-UE-Cd (AUROC = 0.87 ± 0.03, 95% CI: 0.81–0.93, p < 0.001) had better discriminatory power than the APACHE II score (AUROC = 0.82 ± 0.03, 95% CI: 0.75–0.88, p < 0.001), SOFA score (AUROC = 0.78 ± 0.04, 95% CI: 0.71–0.86, p < 0.001), or RIFLE criteria (AUROC = 0.62 ± 0.06, 95% CI: 0.50–0.73, p < 0.001).

Discussion

The results of this 6 month study of mortality in patients at a CCU in Taiwan demonstrated that non-survivors had longer CCU and hospital stays, higher APACHE II, SOFA, and RIFLE scores, and greater D1-UE-Cd. Moreover, more non-survivors had previously diagnosed

Table 5. Forward multivariate Cox analysis of risk factors for hospital death in all study patients, according to baseline variables at the first day in the cardiac care unit. (P > 0.1 to remove)

| Variable                                      | HR (95% CI)       | P      |
|------------------------------------------------|-------------------|--------|
| Respiratory rate (Increase of 1 breath/min)   | 1.139 (1.056–1.228) | 0.001  |
| D1-UE-Cd (Increase of 1 μg/day)               | 3.160 (1.944–5.136) | <0.001 |

Abbreviations here and below: HR: Hazard Ratio; CI: confidence interval.

doi:10.1371/journal.pone.0146173.t005
chronic kidney disease, class III and IV CHF, circulatory shock, acute respiratory failure, and AKI upon CCU admission; non-survivors also had higher mean arterial pressure, pulse and respiratory rates, and levels of AST, BUN, and serum creatinine. Non-survivors were less likely to be male, less likely to smoke, and had lower BMI, Glasgow coma scale score, and serum albumin level. Notably, D1-UE-Cd was significantly associated with mortality after adjusting for other variables by multivariate Cox regression analysis, including APACHE II, SOFA, and RIFLE scores. The HR of mortality associated with each 1 μg/day increase of urinary cadmium was 3.160. Hence, D1-UE-Cd appears to be a good predictor of hospital mortality in critically
ill cardiac patients; the other findings of the present study are similar to the results of previous studies of CCU patients [21,22]. This is the first study to demonstrate that urinary cadmium excretion is significantly associated with mortality in CCU patients.

Many scoring systems [7–11] have been developed to describe the severity of illness in ICU patients and to predict patient outcome following medical care. The APACHE II [10] and SAPS II scores [7] are based a patient’s clinical status during the first 24 h of ICU admission, and the SOFA score [8] quantifies illness severity based on the function or failure rate of different organ system. Although these scoring systems are widely used, they can be complicated and time-consuming in clinical practice. Moreover, use of these scoring systems requires training and adherence to strict guidelines [10], because inter-observer variability can occur when different physicians evaluate the same patient [10,23]. Hence, a simple predictor is needed for critical care patients because more aggressive treatments may be required if there is increased risk of mortality. Compared with these scoring systems, the D1-UE-Cd (recorded upon CCU admission), is a simple and useful predictor of mortality in patients admitted to the CCU. However, more studies are needed to the clinical suitability of this test before it can be widely accepted as an independent predictor of mortality in CCU patients.

Previous studies of general populations have examined the association between urinary cadmium and mortality. For example, Menke et al. [24] demonstrated that environmental cadmium exposure increased the risk of death from all-causes, all cancers, and cardiovascular disease among U.S. men who participated in the Third National Health and Nutrition Examination Survey in 1988–1994. Another study by Cheung et al. [25] showed that urinary cadmium was a predictor of mortality from all-causes, all cancers, and prostate cancer in men, based on data of National Health and Nutrition Examination Survey (NHANES III). Moreover, a 22-year follow-up study by Li et al. [26] of a cadmium-polluted area in Japan suggested a dose-response relationship between cadmium body burden and mortality from cardiovascular diseases, cerebrovascular diseases, and nephritis in the 3119 inhabitants. However, the present study is the first to report a significant association between body cadmium level and mortality in critically ill cardiac patients who have no history of cadmium exposure.

Although the cause of the increased cadmium level in the biological fluids of CCU patients remains uncertain, several in vitro and in vivo studies provide some insight into the cardiac effects of cadmium exposure. In rats, Ferramola et al. [27,28] demonstrated that cadmium may induce myocardial injury by increasing oxidative stress. Ozturk et al. [29] demonstrated that cadmium intoxication can cause deformation of cardiac muscle cells due to an increase of free radicals and lipid peroxidation. In humans, Ponteva et al. [30] showed that the mean blood cadmium level of 47 patients with myocardial infarction was significantly higher than that of 37 control subjects. Smetana et al. [31] reported that 54 patients with dilated cardiomyopathy had higher blood and urinary levels of cadmium than 17 healthy controls. Moreover, Tellez-Plaza et al. [32] performed a prospective cohort study of 3348 adults and showed that elevated urinary cadmium was associated with increased cardiovascular mortality and cardiovascular disease. Taken together with our findings, this suggests that cadmium may play a role in the pathogenesis of cardiovascular diseases. However, further studies are needed to elucidate the mechanism by which cadmium increases the mortality of CCU patients.

In ROC analysis, a parameter with an AUROC of 0.80 or more is considered a good predictor [7,33], and a parameter with an AUROC of 0.70 or less is considered a poor predictor [20,34]. In the present study, our ROC analysis indicated that D1-UE-Cd had the greatest AUROC (0.87 ± 0.03, 95% CI: 0.81–0.93), and was the only parameter whose 95% CI is entirely above 0.80. Moreover, comparison of ROC curves demonstrated that D1-UE-Cd outperformed the SOFA, APACHE II, and RIFLE scoring systems (Fig 1). Furthermore, we performed model calibration by the HL goodness-of-fit test, which determines how well the predicted outcomes

match the observed outcomes throughout a range of risks [18]. An HL chi-square less than 15 and a $p$-value of 0.2–0.8 are considered acceptable [13,35]; thus, our analysis indicated that D1-UE-Cd had good calibration (HL chi-square = 10.869, $p = 0.213$). All of these findings indicate that D1-UE-Cd has high discrimination and calibration in the prediction of mortality for CCU patients, and that it appears to be superior to the SOFA, APACHE II, and RIFLE scoring systems. Hence, D1-UE-Cd is a simple and reliable predictor of mortality in this population. Further studies are needed to examine whether D1-UE-Cd can also be used as an indicator of response to treatment among CCU patients.

Previous studies reported that an elevated level of AST [36] and a lower level of serum albumin [37,38] occur in patients with severe cardiac complications, such as acute myocardial infarction or heart failure. The current study, after adjusting for potential variables by multiple linear regression analysis with backward stepwise procedures, demonstrated that D1-UE-Cd was positively associated with AST and negatively associated with serum albumin. As a non-specific biomarker of myocardial injury, AST may be elevated in critically ill cardiac patients [39]. Cadmium usually accumulates in the liver and kidney [1], and patients with critical cardiac complications (e.g. acute myocardial infarction, class III or IV congestive heart failure, arrhythmia, unstable angina, and aortic dissection) may suffer from severe liver and kidney damage, so damage of these organs may explain the higher level of urinary cadmium in more severely ill patients [6]. Moreover, liver damage may decrease the synthesis of serum albumin in humans. An in vitro study [40] also reported that cadmium (a potent nephrotoxin), can lead to albuminuria by impairing reabsorption and secretion in the renal proximal tubule. However, further studies are needed to verify the mechanisms underlying the relationships of D1-UE-Cd, serum AST, and serum albumin in CCU patients.

There are several limitations of this study. Although the results indicated that D1-UE-Cd can predict hospital mortality in critically ill cardiac patients, the mechanism underlying this relationship is still unclear. Hence, more studies are needed to explore the physiological dynamics of cadmium and what D1-UE-Cd means in this population, and some studies are underway in our research center. Furthermore, the enrolled patients were not an incident cohort of patients with critical cardiac events, so there may have been survivorship bias. However, the association between D1-UE-Cd and mortality remained after adjustment for potential confounding in our multivariate Cox analysis. Additionally, our sample size was somewhat small and the study was performed at a single institution, so the results may not be applicable to CCU patients of other hospitals. Hence, further large-scale multi-center studies are required to confirm our observations.

Conclusions

In summary, this study is the first to demonstrate that D1-UE-Cd in patients admitted to the CCU is independently associated with mortality. This index has good calibration and discrimination, and that it outperformed the APACHE II, SOFA, and RIFLE scoring systems by ROC analysis. Moreover, compared with other scoring systems, measurement of D1-UE-Cd is a single objective variable, and there is no inter-observer variability among physicians. Because of the small number of patients in the present study, the predictive value of cadmium in CCU patients needs further validation. Moreover, additional studies are needed to establish the mechanism by which cadmium exposure increases cardiovascular mortality.

Acknowledgments

We thank the members of the Statistic Center in Chang Gung Memorial Hospital for their invaluable and dedicated assistance.
Author Contributions
Conceived and designed the experiments: CWH CHW. Performed the experiments: KHC. Analyzed the data: DTLT CYL. Contributed reagents/materials/analysis tools: THY PHC. Wrote the paper: CWH WHH.

References
1. Järup L, Berglund M, Elinder CG, Nordberg G, Vahter M. Health effects of cadmium exposure—a review of the literature and a risk estimate. Scand J Work Environ Health. 1998; 24:Suppl-51
2. Järup L. Cadmium overload and toxicity. Nephrol Dial Transplant. 2002; 17:Suppl-9
3. Järup L, Hellstrom L, Alfven T, Carlsson MD, Grubb A, Persson B, et al. Low level exposure to cadmium and early kidney damage: the OSCAR study. Occup Environ Med. 2000; 57:668–72 PMID:10984338
4. Bernard A, Lauwerys R. Effects of cadmium exposure in humans. In: Foulkes, E.C. ed. Handbook of experimental pharmacology. 1986; 80:135–177
5. Buchet JP, Lauwerys R, Roels H, Bernard A, Bruaux P, Ciaeys F, et al. Renal effects of cadmium body burden of the general population. Lancet. 1990; 336(8717):699–702 PMID:1975890
6. Lin JL, Lin-Tan DT, Chu PH, Chen YC, HuangYL, Ho TC, et al. Cadmium excretion predicting hospital mortality and illness severity of critically ill medical patients. Crit Care Med. 2009; 37:957–62 doi: 10.1097/CCM.0b013e318198675c PMID: 19237903
7. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993; 270:2957–63 PMID:8254858
8. Vincent JL, Moreno R, Takala J, Willatts S, De MA, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996; 22:707–10 PMID:8844239
9. Pettilia V, Pettilia M, Sama S, Voutilainen P, Takkunen O. Comparison of multiple organ dysfunction scores in the prediction of hospital mortality in the critically ill. Crit Care Med. 2002; 30:1705–11 PMID:12163780
10. Polderman KH, Girbes AR, Thijs LG, Strack van Schijndel RJ. Accuracy and reliability of APACHE II scoring in two intensive care units Problems and pitfalls in the use of APACHE II and suggestions for improvement. Anaesthesia. 2001; 56:47–50 PMID:11167435
11. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int. 2008; 73:538–46 PMID:18160961
12. Lakkireddy D, Vacek J, Harris W, Gowda M, Pendyala K, Murray C. Modified Mid America Heart Institute Coronary Care Unit scoring system—a new comprehensive prognostic index for Coronary Care Unit patients. Med Sci Monit. 2005; 11:CR95–CR99 PMID:15735569
13. Rosenberg AL. Recent innovations in intensive care unit risk-prediction models. Curr Opin Crit Care. 2002; 8:321–30 PMID:12384693
14. Tran DD, Groeneveld AB, van der Meulen J, Nauta JJ, Strack van Schijndel RJ, Thijs LG. Age, chronic disease, sepsis, organ system failure, and mortality in a medical intensive care unit. Crit Care Med. 1990; 18:474–9 PMID:2328591
15. Knaus WA, Draper EA, Wagner DP. Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13:818–29 PMID:3928249
16. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute Dialysis Quality Initiative workgroup. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004; 8:R204–R212 PMID:15312219
17. Jin T, Nordberg M, Frech W, Dumont X, Bernard A, Ye TT, et al. Cadmium biomonitoring and renal dysfunction among a population environmentally exposed to cadmium from smelting in China (ChinaCad). BioMetals. 2002; 15:397–410 PMID:12405535
18. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982; 15:92–106
19. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983; 148:839–43 PMID:6878708
20. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143:29–36 PMID:7063747
21. Hein OV, Bimbaum J, Werneck K, England M, Konertz W, Spies C. Prolonged intensive care unit stay in cardiac surgery: risk factors and long-term survival. Ann Thorac Surg. 2006; 81:880–5 PMID: 16488688

22. Ryan TA, Rady MY, Bashour CA, Leventhal M, Lytle B, Starr NJ. Predictors of outcome in cardiac surgical patients with prolonged intensive care stay. Chest. 1997; 112:1035–42 PMID: 9377914

23. Polderman KH, Jorna EM, Girbes AR. Inter-observer variability in APACHE II scoring: effect of strict guidelines and training. Intensive Care Med. 2001; 27:1365–9 PMID: 11511950

24. Menke A, Muntner P, Silberfeld EK, Platz EA, Guallar E. Cadmium levels in urine and mortality among U.S. adults. Environ Health Perspect. 2009; 117:190–6 doi: 10.1289/ehp.11236 PMID: 19270787

25. Cheung MR, Kang J, Ouyang D, Yeung V. Association between urinary cadmium and all cause, all cancer and prostate cancer specific mortalities for men: an analysis of national health and nutrition examination survey (NHANES III) data. Asian Pac J Cancer Prev. 2014; 15:483–8 PMID: 24528078

26. Li Q, Nishijo M, Nakagawa H, Morikawa Y, Nakamura K, et al. Relationship between urinary cadmium and mortality in habitants of a cadmium-polluted area: a 22-year follow-up study in Japan. Chin Med J. 2011; 124:3504–9 PMID: 22340168

27. Ferramola ML, Perez Diaz MF, Honore SM, Sanchez SS, Anton RI, Anzulovich AC, et al. Cadmium-induced oxidative stress and histological damage in the myocardium. Effects of a soy-based diet. Toxicol Appl Pharmacol. 2012; 265:380–9 doi: 10.1016/j.taap.2012.09.009 PMID: 22995158

28. Ferramola ML, Anton RI, Anzulovich AC, Gimenez MS. Matrix metalloproteinase 2 expression following sub-chronic and chronic oral cadmium exposure in rats. Toxicol Appl Pharmacol. 2011; 32:17–26 doi: 10.1016/j.taap.2011.03.002 PMID: 21787725

29. Ozturk IM, Buyukakilli B, Balli E, Cimen B, Gunes S, Erdogan S. Determination of acute and chronic effects of cadmium on the cardiovascular system of rats. Toxicol Mech Methods. 2009; 19:308–17 doi: 10.1080/15376510802662751 PMID: 19778222

30. Ponteva M, Elomaa I, Backman H, Hansson L, Kilpio J. Blood cadmium and plasma zinc measurements in acute myocardial infarction. Eur J Cardiol. 1979; 9:379–91 PMID: 456396

31. Smetana R, Glogar D, Gemeiner M. [Heavy metal and trace element concentrations in patients with idiopathic dilated cardiomyopathy]. [German]. Wien Klin Wochenschr. 1985; 97:697–701 PMID: 4060731

32. Tellez-Plaza M, Guallar E, Howard BV, Umans JG, Francesconi KA, Goessler W, et al. Cadmium exposure and incident cardiovascular disease. Epidemiology. 2013; 24:421–9 doi:10.1097/EDE.0b013e31828b0631 PMID: 23514838

33. Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991; 100:1619–36 PMID: 1959406

34. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clinical Chemistry. 1993; 39:561–77 PMID: 8472349

35. Angua DC, Clermont G, Kramer DJ, Linde-Zwirble WT, Pinsky MR. Short-term and long-term outcome prediction with the Acute Physiology and Chronic Health Evaluation II system after orthotopic liver transplantation. Critical Care Med. 2000; 28:150–6

36. Shah H, Haridas N. A serial follow up study of cardiac marker enzymes during the week after acute myocardial infarction. Indian J Clin Biochem. 2007; 22:33–6 doi: 10.1007/BF02912878 PMID: 23105649

37. Arques S, Ambrosi P. Human serum albumin in the clinical syndrome of heart failure. J Card Fail. 2011; 17:451–8 doi: 10.1016/j.cardfail.2011.02.010 PMID: 21624732

38. Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation. 2002; 106:2919–24 PMID: 12460872

39. Ladenson JH. Reflections on the evolution of cardiac biomarkers. Clin Chem. 2012; 58:21–4 doi: 10.1373/clinchem.2011.165852 PMID: 21865481

40. Gena P, Calamita G, Guggino WB. Cadmium impairs albumin reabsorption by down-regulating megalin and ClC5 channels in renal proximal tubule cells. Environ Health Perspect. 2010; 118:1551–6 doi: 10.1289/ehp.0901874 PMID: 20576581